Board meeting on Oct 30 to approve Q2 FY26 results

Results View source PDF Explain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹75.84

prior close

₹79.63

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+4.3% vs market

Pharmaceuticals peers, median of 172sector-0.0%+5.0% vs sector

On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.7+4.3-0.0+5.0

Next day

+10.2-1.0+11.2-0.8+11.1

+15.8-0.3+16.0-0.6+16.3

+13.4-1.9+15.4-1.9+15.3

+11.2-4.5+15.7-3.5+14.7

+9.0-5.5+14.4-4.4+13.4

+5.5-7.3+12.8-4.4+9.9

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lyka Labs has informed BSE that its Board of Directors will meet on Friday, 30 October 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended 30 September 2026, together with the Limited Review Report from the statutory auditor.

Likely market impact

Routine quarterly results announcement; no immediate impact on shareholders until results are declared.